Gujarat Exclusive >

coronavirus vaccine

First batch of COVID-19 vaccine received by Ahmedabad, 12 other cities

With pan India vaccination for COVID-19 all set to begin from January 16, the first batch of Serum Institute of India’s ‘Covishield’ left Pune for 13 cities including Ahmedabad. The first batch of the vaccine has been already received by Gujarat. Health minister Nitin Patel was present at the Ahmedabad airport to receive the stock....

Pfizer seeks nod for its COVID-19 vaccine in India

US-based vaccine major Pfizer’s India unit has approached the Drugs Controller General of India (DCGI) for emergency use authorisation (EUA) for its COVID-19 vaccine. Following the development, Pfizer India has become the first pharmaceutical firm in the country to seek EUA for its COVID-19 vaccine. Notably, the company’s parent entity has already secured similar...

UK grants approval to Pfizer’s COVID-19 vaccine, vaccination to start next week

US-based vaccine maker Pfizer and its German partner BioNTech on Wednesday announced that they have secured emergency use authorisation for their COVID-19 vaccine in the UK. The development has made the UK one of the first countries to start immunisation of its population, as early as next week, against the deadly virus that has affected...

PM Modi likely to visit Serum Institute on Saturday

Prime Minister Narendra Modi is likely to visit the Serum Institute of India (SII), one of the world’s largest vaccine manufacturers, in Pune on Saturday. Notably, SII has joined hands with AstraZeneca and the University of Oxford for the mass-production of their vaccine candidate. The Union government has granted permission to seven firms for manufacture...

India in talks with Moderna after its COVID-19 vaccine shows efficacy of 94.5%

With COVID-19 cases, as well as deaths, increasing with each passing day, a vaccine against the deadly virus seems to be the only solution to contain the pandemic. While there are several vaccine candidates that are at various stages of clinical trials, some of them have shown promising results with an efficacy of over 90...

Pfizer, BioNTech’s COVID-19 vaccine found 90% effective in phase 3 trial

Pfizer and BioNTech on Monday announced that their mRNA-based vaccine candidate, BNT162b2, has been found to be effective against COVID-19 in participants without prior evidence of coronavirus infection. The results are based on the first interim efficacy analysis conducted on November 8 by an external, independent Data Monitoring Committee (DMC) from the phase 3 clinical...

Hope for a vaccine against COVID-19 by year-end: WHO

At a time when the coronavirus pandemic has engulfed the entire world with thousands of people dying every day, a vaccine seems to be the only hope. However, there is still no clarity on when a safe vaccine will be available, with various vaccine manufacturers working on different deadlines. In such a situation, a ray...

Harsh Vardhan says 25 cr Indians to be vaccinated by July 2021

Union health minister Harsh Vardhan on Sunday said that the government aims to administer 400-500 million doses of the coronavirus vaccine to approximately 25 crore people by July 2021. Harsh Vardhan said that there is an expert body that is looking into all aspects related to the coronavirus vaccines. He added that the Union government...

Russia claims success in developing COVID-19 vaccine

In a breakthrough that might help mankind in overcoming the dangers posed by the coronavirus pandemic, Russia has claimed that it has developed a COVID-19 vaccine. Russian President Vladimir Putin announced the development on Tuesday. It paves the way for the mass immunisation of the Russian population. However, the final stage of clinical trials to...

Serum Institute gets $150 mn funding for COVID-19 vaccine

The Bill and Melinda Gates Foundation and GAVI vaccines alliance have decided to provide funding of $150 million to the Serum Institute of India. The funding will be provided to Serum Institute to make 100 million COVID-19 vaccine doses for India and other developing economies by 2021. The vaccine to be priced at $3 per...

Herd immunity against COVID-19 not an option for India

The Centre on Thursday said India cannot rely on herd immunity as a strategy option in the battle against COVID-19. The Ministry of Health and Family Welfare said herd immunity is not an option for a populous country like India. Herd immunity is a term used to describe a stage where enough people become resistant...

Vaccine candidate developed by Oxford found safe, induces immune reaction

The vaccine candidate developed at the University of Oxford is safe and induces immune reaction, preliminary results released and published in the medical journal The Lancet on Monday said, raising hopes for a cure for COVID-19 that has killed tens of thousands and disrupted human activity across the globe. Explaining how the vaccine works, study...